Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Korean J Ophthalmol. 2021 Dec;35(6):467-475. doi: 10.3341/kjo.2021.0068. Epub 2021 Oct 12.
To investigate ocular surface diseases and changes in the quality of life of patients using glaucoma medications.
Participants were divided into the normal (31 individuals, 62 eyes) and glaucoma medication (30 patients, 60 eyes) groups. Changes in tear break-up time, lipid layer thickness (LLT), corneal and conjunctival staining scores, ocular surface disease index (OSDI), and Visual Function Questionnaire 25 (VFQ-25) score were assessed for 1 year.
The change in mean LLT was lower in glaucomatous eyes than in control eyes (p = 0.019) after 1 year. The results of OSDI deteriorated (p' = 0.008), but conjunctival staining and Schirmer test results showed improvement in glaucomatous eyes compared to those in control eyes (p' =0.035 and 0.009, respectively). The average LLT decreased at 6 and 12 months, but there was no change at 24 months. In pairwise analysis, the decrease in LLT over the first 6 months was statistically significant (p < 0.001) and remained unchanged until 24 months. Among the VFQ items, scores for near activity and social function deteriorated over 1 year in the medication group (p' = 0.033 and 0.015, respectively). However, there was no difference in the total VFQ score.
Significant reduction in LLT and deterioration of OSDI were observed in the medication group compared to the control group. However, this deterioration was observed only in the first 6 months. There was no significant difference in the VFQ total score. Nonetheless, there were significant differences in near activity and social function between the control and medication groups. Therefore, the results of this study showed that although glaucoma medication worsened eye dryness, the change was limited and did not worsen the quality of life. Glaucoma medication should be used with the consideration that they can limit near activity and social functioning.
调查使用青光眼药物患者的眼表疾病和生活质量变化。
将参与者分为正常组（31 人，62 只眼）和青光眼药物组（30 例，60 只眼）。在 1 年内评估泪膜破裂时间、脂质层厚度（LLT）、角膜和结膜染色评分、眼表疾病指数（OSDI）和视觉功能问卷 25（VFQ-25）评分的变化。
1 年后，青光眼组的平均 LLT 变化低于对照组（p=0.019）。OSDI 结果恶化（p'=0.008），但与对照组相比，结膜染色和 Schirmer 试验结果显示青光眼组有改善（p'=0.035 和 0.009）。平均 LLT 在 6 个月和 12 个月时下降，但在 24 个月时没有变化。在成对分析中，前 6 个月 LLT 的下降具有统计学意义（p<0.001），并持续到 24 个月。在 VFQ 项目中，药物组的近活动和社会功能评分在 1 年内恶化（p'=0.033 和 0.015）。然而，VFQ 总分没有差异。
与对照组相比，药物组的 LLT 明显减少，OSDI 恶化。然而，这种恶化仅在最初的 6 个月观察到。VFQ 总分没有显著差异。尽管如此，对照组和药物组在近活动和社会功能方面存在显著差异。因此，本研究结果表明，尽管青光眼药物会加重眼睛干燥，但这种变化是有限的，不会降低生活质量。在使用青光眼药物时，应考虑到它们可能会限制近活动和社会功能。
